Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22147941 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
Condition: 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
Interventions: Biological: GVAX Pancreas Vaccine;   Biological: CRS-207;   Drug: gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib;   Drug: cyclophosphamide

Indicates status has not been verified in more than two years